An investigational therapy is demonstrating preclinical promise against non-Hodgkin lymphoma by boosting natural killer cells and efficiently annihilating the malignancy without toxicity to the patient, a team of cancer biologists ...
Scientists at EPFL have developed "lymphomoids," a pioneering cancer model that preserves the structure and multicellular composition of lymphoma tumors in the lab. Lymphomoids offer an innovative way to test the efficacy ...
Dec 18, 2024
0
13
Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone lymphoma.
Dec 9, 2024
0
47
A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92%, suggesting a new standard therapy for the disease. The New England Journal ...
Oct 16, 2024
1
75
Patients with a rare blood cancer that has relapsed or become resistant to treatment have shown a high response rate to a potent new immunotherapy drug, in a Peter Mac-led clinical trial.
Oct 7, 2024
0
0
Blood cancer is not a diagnosis anyone wants to receive, but understanding the different types of this disease and how best to catch them early is essential, one expert says.
Sep 30, 2024
0
0
One July evening, Allison Rosenthal, D.O., received a flurry of texts with exclamations like, "Yo, my doctor friend is famous!"
Sep 9, 2024
0
0
Income and area-level disadvantage are the largest contributors to racial differences in financial hardship among older U.S. adults with cancer, according to a study published online June 18 in Cancer.
Jul 2, 2024
0
0
Checkpoint inhibitor therapies can be thought of as the molecular "brake release" for the immune system. These drugs eliminate the protein barriers that impede the immune system from recognizing and targeting cancer cells ...
Jun 20, 2024
0
42
A pair of biostatisticians at the U.S. National Cancer Institute, has found that members of Generation X are more susceptible to many kinds of cancers than their parents or grandparents were. In their study, published in ...
